GLP-3 vs Retatrutide: What Do the Different Names Mean?

GLP-3 is an informal label; retatrutide is the name of a specific compound being studied. People use “GLP-3” when discussing retatrutide because it acts on three hormone receptors. The phrase is not a scientific drug classification. Lilly explains the nickname.

That answers the naming question, but a product listing raises another one: what material is actually being offered? A familiar name on a page cannot answer that by itself. Here is how to separate the research name, the nickname and the wording on a seller’s label.

As checked on September 14, 2026, retatrutide is not FDA-approved. A research-use label does not make a product an approved medicine. FDA warns about unapproved products marketed to consumers for human use under research labels. Read FDA’s current notice.

The names do different jobs

Start by asking what kind of name you are reading.

The original retatrutide trial abstract pairs retatrutide with LY3437943. FDA’s Zepbound approval announcement identifies tirzepatide as the ingredient in both Zepbound and Mounjaro. The informal terms above have a different role: they may help you understand a conversation or find a page, but they do not authenticate a product.

Why people say GLP-3

A receptor is a cell’s signal receiver. An agonist activates a receptor. Retatrutide is described as a triple receptor agonist because one molecule activates receptors for three hormones: GLP-1, GIP and glucagon.

GLP-1 means glucagon-like peptide-1. GIP means glucose-dependent insulinotropic polypeptide. You do not need to memorize the long names to understand the distinction: three describes the receptor targets, not three peptides mixed together. The research abstract describes the three targets, and Lilly identifies retatrutide as a single molecule.

The nickname points toward a compound; “triple” describes its receptor targets. This is a concept diagram, not a test result. Sources: Lilly’s explanation and the original trial abstract.

What the names look like on WPA

We checked the public WPA comparison on September 14, 2026. Entering GLP-3 in its peptide search returned Retatrutide. Selecting that result opened the Retatrutide comparison. This is a useful way to find entries when you start with the nickname.

Try the lookup on WPA’s Retatrutide vendors page. The page brings listings together under the Retatrutide name. That grouping helps you navigate; it does not establish what is inside a seller’s vial.

The distinction becomes clearer when you follow a listing. Two selected links in that category displayed different names:

These are examples of displayed wording, not verified synonyms for identical contents. We selected them to illustrate the naming problem, not to rank suppliers. We did not test products or authenticate their reports. Pages can also change after a link is added to a comparison site.

The useful next question is therefore more specific than “Does this name look familiar?” It is: Which compound does the seller say this listing contains, and what evidence relates to that material?

When a listing uses a different name

First, look for an explicit compound name in the seller’s description or documentation. If it only repeats a shortened label, ask what that label identifies. Do not fill in the missing answer from a directory category or a similar-looking name.

Next, compare that identification with the sample name and batch or lot on the full certificate of analysis, or COA. A COA is a report of analysis for a sample; a batch or lot identifies a group of material. Check which report the seller says applies to the listing. If the connection is missing or the names disagree, leave the identity question open until it is explained.

For the detailed report checks, use WPA’s guide to reading a peptide COA. Following these documents helps you understand the claim and its evidence. It does not turn a research product into an approved treatment or establish that every vial matches a tested sample.

Questions about other names

Is GLP-3 RT the same as retatrutide?

GLP-3 RT has been used as a seller label for retatrutide. An FDA warning letter records that naming. The letter concerns unapproved drugs; it is not an endorsement or a test of a vial’s contents.

So the label can tell you what the seller means, but it cannot verify the material. Check the explicit compound identification and the documentation for the product being offered. Our two-example check above does not verify every product sold under this or another shortened name.

Does retatrutide have an FDA-approved brand name?

There is no FDA-approved retatrutide product as of the September 14, 2026 source check. That is different from claiming that nobody has proposed a future trade name. Zepbound and Mounjaro are existing tirzepatide brands, not retatrutide brands. See FDA’s retatrutide notice and its brand-ingredient explanation.

Start with the compound name

Use retatrutide to connect the research to the comparison category. Treat GLP-3 and other shortened wording as clues to investigate. When names differ, check the seller’s actual claim and the material its report describes before drawing a conclusion.

You can review the entries grouped under Retatrutide to compare the displayed listings and available saved COA details. Then follow through to the seller’s current page and full report. The comparison is a starting point for reviewing information, not a guarantee of identity, quality or suitability for human use.

Some vendor links on WPA’s comparison page are affiliate links. WPA may earn a commission.

How this article was prepared

This article was prepared with AI assistance. Its terminology uses the linked primary research and official sources; its listing examples come from a bounded check of public WPA and seller pages on September 14, 2026. One search term and two selected seller labels illustrate the issue, rather than represent the whole market. We reviewed website content and published sources; we did not conduct laboratory testing or medical review.